An update on pharmacologic approaches to bronchopulmonary dysplasia

作者：Ghanta Sailaja; Leeman Kristen Tropea; Christou Helen^*

来源：Seminars in Perinatology, 2013, 37(2): 115-123.

DOI：10.1053/j.semperi.2013.01.008

• Prematurity
• Low birth weight
• Chronic lung disease

Bronchopulmonary dysplasia (BPD) is the most prevalent long-term morbidity in surviving extremely preterm infants and is linked to increased risk of reactive airways disease, pulmonary hypertension, post-neonatal mortality, and adverse neurodevelopmental outcomes. BPD affects approximately 20% of premature newborns, and up to 60% of premature infants born before completing 26 weeks of gestation. It is characterized by the need for assisted ventilation and/or supplemental oxygen at 36 weeks postmenstrual age. Approaches to prevention and treatment of BPD have evolved with improved understanding of its pathogenesis. This review will focus on recent advancements and detail current research in pharrnacotherapy for BPD. The evidence for both current and potential future experimental therapies will be reviewed in detail. As our understanding of the complex and multifactorial pathophysiology of BPD changes, research into these current and future approaches must continue to evolve.

• 出版日期2013-4